GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

GLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

Results met the primary endpoint: percentage change from baseline in body weight after 36 ... 16.7% at the 6mg dose at 24 weeks. Hengrui has ongoing Phase III clinical trials for its GLP-1/GIP ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

WVU recently performed its first DMR procedure under the leadership of Shailendra Singh, MD, director of bariatric endoscopy and associate professor in the division of gastroenterology and hepatology ...

Competition is tightening, with Eli Lilly (NYSE:LLY) racing alongside Novo in the GLP-1 space. Novo's pipeline powerhouse, CagriSema, recently fell short of its weight-loss goals, but its ...